Aussie Research Finds Three-Drug Combo With AstraZeneca’s Casodex Kills Prostate Cancer
This article was originally published in PharmAsia News
Executive Summary
Australian researchers report that a combination of three prostate drugs is effective in killing cancer cells with fewer side effects than current drugs. The combination centers AstraZeneca's Casodex (bicalutamide) in low doses to make either of the other two drugs 10 times more effective in their treatment of advanced prostate cancer. The researchers said their laboratory experiments indicate none of the three drugs is as effective in killing prostate cancer cells if used alone. The other drugs used in the experiments were inhibitors 17AAG and Merck's Zolinza (vorinostat). The scientists have begun Phase I clinical trials on the combination. (Click here for more
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.